 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 July 1998 | Volume 129 Issue 1 | Pages 38-41
Background: Troglitazone is a new drug for the treatment of type 2 diabetes. Although mild liver injury occurred in 1.9% of participants in controlled trials, the U.S. Food and Drug Administration has received reports of five postmarketing cases of severe liver disease that resulted in death or liver transplantation.
Objective: To report the clinical and histopathologic characteristics of a patient with troglitazone-associated severe liver injury leading to transplantation.
Design: Case report.
Setting: Two university hospitals.
Patient: A 55-year-old woman taking troglitazone, 400 mg/d, and insulin, 120 U/d.
Intervention: Discontinuation of troglitazone therapy, pretransplantation liver biopsy, and liver transplantation.
Results: Early nonspecific symptoms were attributed to other causes and were not evaluated. After the patient had used troglitazone for 3.5 months, massive loss of liver parenchyma and symptoms of liver failure developed, necessitating liver transplantation.
Conclusion: Troglitazone may cause subfulminant liver failure.
BRIEF COMMUNICATION
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Related articles in Annals:
This article has been cited by other articles:
 |
|
 |
|
  M. Collino, N. S.A. Patel, and C. Thiemermann Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 179 - 197. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Misbin Evaluating the Safety of Diabetes Drugs: Perspective of a Food and Drug Administration insider Diabetes Care, October 1, 2005; 28(10): 2573 - 2576. [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Baughman, R. A. Graham, K. Wells-Knecht, I. S. Silver, L. O. Tyler, M. Wells-Knecht, and Z. Zhao METABOLIC ACTIVATION OF PIOGLITAZONE IDENTIFIED FROM RAT AND HUMAN LIVER MICROSOMES AND FRESHLY ISOLATED HEPATOCYTES Drug Metab. Dispos., June 1, 2005; 33(6): 733 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Maniratanachote, K. Minami, M. Katoh, M. Nakajima, and T. Yokoi Chaperone Proteins Involved in Troglitazone-Induced Toxicity in Human Hepatoma Cell Lines Toxicol. Sci., February 1, 2005; 83(2): 293 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Lee and J. R. Senior Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions Toxicol Pathol, January 1, 2005; 33(1): 155 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Brettenthaler, C. De Geyter, P. R. Huber, and U. Keller Effect of the Insulin Sensitizer Pioglitazone on Insulin Resistance, Hyperandrogenism, and Ovulatory Dysfunction in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3835 - 3840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Sawant, A. V. Dnyanmote, K. Shankar, P. B. Limaye, J. R. Latendresse, and H. M. Mehendale Potentiation of Carbon Tetrachloride Hepatotoxicity and Lethality in Type 2 Diabetic Rats J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 694 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Lee Drug-Induced Hepatotoxicity N. Engl. J. Med., July 31, 2003; 349(5): 474 - 485. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Chan, A. Truman, J. H. Gurwitz, J. S. Hurley, B. Martinson, R. Platt, J. E. Everhart, R. H. Moseley, N. Terrault, L. Ackerson, et al. A Cohort Study of the Incidence of Serious Acute Liver Injury in Diabetic Patients Treated With Hypoglycemic Agents Arch Intern Med, March 24, 2003; 163(6): 728 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Lebovitz, M. Kreider, and M. I. Freed Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction Diabetes Care, May 1, 2002; 25(5): 815 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Buchweitz, P. E. Ganey, S. J. Bursian, and R. A. Roth Underlying Endotoxemia Augments Toxic Responses to Chlorpromazine: Is There a Relationship to Drug Idiosyncrasy? J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 460 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Graham, C. R. Drinkard, D. Shatin, Y. Tsong, and M. J. Burgess Liver Enzyme Monitoring in Patients Treated With Troglitazone JAMA, August 15, 2001; 286(7): 831 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Azziz, D. Ehrmann, R. S. Legro, R. W. Whitcomb, R. Hanley, A. G. Fereshetian, M. O’Keefe, and M. N. Ghazzi Troglitazone Improves Ovulation and Hirsutism in the Polycystic Ovary Syndrome: A Multicenter, Double Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1626 - 1632. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Funk, C. Ponelle, G. Scheuermann, and M. Pantze Cholestatic Potential of Troglitazone as a Possible Factor Contributing to Troglitazone-Induced Hepatotoxicity: In Vivo and in Vitro Interaction at the Canalicular Bile Salt Export Pump (Bsep) in the Rat Mol. Pharmacol., March 1, 2001; 59(3): 627 - 635. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca Nonhypoglycemic Effects of Thiazolidinediones Ann Intern Med, January 2, 2001; 134(1): 61 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Lebovitz, J. F. Dole, R. Patwardhan, E. B. Rappaport, and M. I. Freed Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 280 - 288. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Lenhard and W. B. Funk Failure to Develop Hepatic Injury From Rosiglitazone in a Patient With a History of Troglitazone-Induced Hepatitis Diabetes Care, January 1, 2001; 24(1): 168 - 169. [Full Text]
|
|
|
|
 |
|
 S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]
|
|
|
|
|
|
K. A. Prendergast, C. L. Berg, and R. Wisniewski Troglitazone-Associated Hepatotoxicity Treated Successfully with Steroids Ann Intern Med, November 7, 2000; 133(9): 751 - 751. [Full Text] [PDF]
|
|
|
|
|
|
V. E. Kostrubsky, J. F. Sinclair, V. Ramachandran, R. Venkataramanan, Y. H. Wen, E. Kindt, V. Galchev, K. Rose, M. Sinz, and S. C. Strom The Role of Conjugation in Hepatotoxicity of Troglitazone in Human and Porcine Hepatocyte Cultures Drug Metab. Dispos., October 1, 2000; 28(10): 1192 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Isley and J. C. Oki Rosiglitazone and Liver Failure Ann Intern Med, September 5, 2000; 133(5): 393 - 393. [Full Text] [PDF]
|
|
|
|
|
|
S. Jagannath and R. Rai Rapid-Onset Subfulminant Liver Failure Associated with Troglitazone Ann Intern Med, April 18, 2000; 132(8): 677 - 677. [Full Text] [PDF]
|
|
|
|
|
|
E. R. Schiff Update in Hepatology Ann Intern Med, March 21, 2000; 132(6): 460 - 466. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Forman, D. A. Simmons, and R. H. Diamond Hepatic Failure in a Patient Taking Rosiglitazone Ann Intern Med, January 18, 2000; 132(2): 118 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Al-Salman, H. Arjomand, D. G. Kemp, and M. Mittal Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report Ann Intern Med, January 18, 2000; 132(2): 121 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ramachandran, V. E. Kostrubsky, B. J. Komoroski, S. Zhang, K. Dorko, J. E. Esplen, S. C. Strom, and R. Venkataramanan Troglitazone Increases Cytochrome P-450 3A Protein and Activity in Primary Cultures of Human Hepatocytes Drug Metab. Dispos., October 1, 1999; 27(10): 1194 - 1199. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Grundy, I. J. Benjamin, G. L. Burke, A. Chait, R. H. Eckel, B. V. Howard, W. Mitch, S. C. Smith Jr, and J. R. Sowers Diabetes and Cardiovascular Disease : A Statement for Healthcare Professionals From the American Heart Association Circulation, September 7, 1999; 100(10): 1134 - 1146. [Full Text] [PDF]
|
|
|
|
|
|
D. Altkorn, K. Roach, S. Stern, and W. Levinson Update in General Internal Medicine Ann Intern Med, August 3, 1999; 131(3): 199 - 206. [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Demetri, C. D. M. Fletcher, E. Mueller, P. Sarraf, R. Naujoks, N. Campbell, B. M. Spiegelman, and S. Singer Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma PNAS, March 30, 1999; 96(7): 3951 - 3956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. I. Misbin Troglitazone-Associated Hepatic Failure Ann Intern Med, February 16, 1999; 130(4_Part_1): 330 - 330. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Herrine and C. Choudhary Severe Hepatotoxicity Associated with Troglitazone Ann Intern Med, January 19, 1999; 130(2): 163 - 164. [Full Text] [PDF]
|
|
Article
